Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
Summary
This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.
COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.
IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.
Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.
Scope
Reasons to buy
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 11
2 Introduction 12
2.1 Chronic Respiratory Disease Report Coverage 12
2.2 Asthma - Overview 12
2.3 Chronic Obstructive Pulmonary Disease (COPD) - Overview 12
2.4 Idiopathic Pulmonary Fibrosis - Overview 12
3 Therapeutics Development 13
3.1 Asthma 13
3.2 Chronic Obstructive Pulmonary Disease (COPD) 33
3.3 Idiopathic Pulmonary Fibrosis 51
4 Therapeutics Assessment 65
4.1 Asthma 65
4.2 Chronic Obstructive Pulmonary Disease (COPD) 81
4.3 Idiopathic Pulmonary Fibrosis 94
5 Companies Involved in Therapeutics Development 106
5.1 Asthma 106
5.2 Chronic Obstructive Pulmonary Disease (COPD) 172
5.3 Idiopathic Pulmonary Fibrosis 223
6 Dormant Projects 259
6.1 Asthma 259
6.2 Chronic Obstructive Pulmonary Disease (COPD) 279
6.3 Idiopathic Pulmonary Fibrosis 302
7 Discontinued Products 307
7.1 Asthma 307
7.2 Chronic Obstructive Pulmonary Disease (COPD) 311
7.3 Idiopathic Pulmonary Fibrosis 316
8 Product Development Milestones 317
8.1 Asthma 317
8.2 Chronic Obstructive Pulmonary Disease (COPD) 331
8.3 Idiopathic Pulmonary Fibrosis 345
9 Appendix 360
9.1 Methodology 360
9.2 Coverage 360
9.3 Secondary Research 360
9.4 Primary Research 360
9.5 Expert Panel Validation 360
9.6 Contact Us 360
9.7 Disclaimer 361
List of Tables
Table 1: Number of Products under Development for Asthma 13
Table 2: Number of Products under Development by Companies, Asthma 15
Table 3: Number of Products under Development by Universities/Institutes, Asthma 20
Table 4: Products under Development by Companies, Asthma 21
Table 5: Products under Development by Universities/Institutes, Asthma 31
Table 6: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) 33
Table 7: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34
Table 8: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38
Table 9: Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 39
Table 10: Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 50
Table 11: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51
Table 12: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 53
Table 13: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56
Table 14: Products under Development by Companies, Idiopathic Pulmonary Fibrosis 57
Table 15: Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 64
Table 16: Number of Products by Stage and Target, Asthma 66
Table 17: Number of Products by Stage and Mechanism of Action, Asthma 72
Table 18: Number of Products by Stage and Route of Administration, Asthma 78
Table 19: Number of Products by Stage and Molecule Type, Asthma 80
Table 20: Number of Products by Stage and Target, Chronic Obstructive Pulmonary Disease (COPD) 82
Table 21: Number of Products by Stage and Mechanism of Action, Chronic Obstructive Pulmonary Disease (COPD) 87
Table 22: Number of Products by Stage and Route of Administration, Chronic Obstructive Pulmonary Disease (COPD) 92
Table 23: Number of Products by Stage and Molecule Type, Chronic Obstructive Pulmonary Disease (COPD) 93
Table 24: Number of Products by Stage and Target, Idiopathic Pulmonary Fibrosis 95
Table 25: Number of Products by Stage and Mechanism of Action, Idiopathic Pulmonary Fibrosis 99
Table 26: Number of Products by Stage and Route of Administration, Idiopathic Pulmonary Fibrosis 103
Table 27: Number of Products by Stage and Molecule Type, Idiopathic Pulmonary Fibrosis 105
Table 28: Asthma - Pipeline by 4D Pharma PLC 106
Table 29: Asthma - Pipeline by AB Science SA 106
Table 30: Asthma - Pipeline by AbbVie Inc 107
Table 31: Asthma - Pipeline by Abeome Corp 107
Table 32: Asthma - Pipeline by Accolade Pharmaceuticals LLC 108
Table 33: Asthma - Pipeline by Adamis Pharmaceuticals Corp 108
Table 34: Asthma - Pipeline by ALK-Abello AS 109
Table 35: Asthma - Pipeline by Allergan Plc 110
Table 36: Asthma - Pipeline by Allergopharma GmbH & Co KG 111
Table 37: Asthma - Pipeline by Almirall SA 111
Table 38: Asthma - Pipeline by Amgen Inc 112
Table 39: Asthma - Pipeline by Amphastar Pharmaceuticals Inc 112
Table 40: Asthma - Pipeline by AnaptysBio Inc 113
Table 41: Asthma - Pipeline by AnGes Inc 113
Table 42: Asthma - Pipeline by Antisense Therapeutics Ltd 114
Table 43: Asthma - Pipeline by Apollo Endosurgery Inc 114
Table 44: Asthma - Pipeline by ASIT Biotech SA 115
Table 45: Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd 115
Table 46: Asthma - Pipeline by Astellas Pharma Inc 116
Table 47: Asthma - Pipeline by AstraZeneca Plc 117
Table 48: Asthma - Pipeline by Aurigene Discovery Technologies Ltd 117
Table 49: Asthma - Pipeline by Biocon Ltd 118
Table 50: Asthma - Pipeline by BiosanaPharma BV 118
Table 51: Asthma - Pipeline by Biotec Pharmacon ASA 119
Table 52: Asthma - Pipeline by Boehringer Ingelheim GmbH 119
Table 53: Asthma - Pipeline by Celon Pharma SA 120
Table 54: Asthma - Pipeline by Chiesi Farmaceutici SpA 121
Table 55: Asthma - Pipeline by Crossject SA 121
Table 56: Asthma - Pipeline by CrystalGenomics Inc 122
Table 57: Asthma - Pipeline by CSL Ltd 123
Table 58: Asthma - Pipeline by CSPC Pharmaceutical Group Limited 123
Table 59: Asthma - Pipeline by Cumberland Pharmaceuticals Inc 124
Table 60: Asthma - Pipeline by Cynata Therapeutics Ltd 124
List of Figures
Figure 1: Number of Products under Development for Asthma 13
Figure 2: Number of Products under Development by Companies, Asthma 14
Figure 3: Number of Products under Development by Universities/Institutes, Asthma 19
Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD 33
Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34
Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38
Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51
Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 52
Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56
Figure 10: Number of Products by Top 10 Targets, Asthma 65
Figure 11: Number of Products by Stage and Top 10 Targets, Asthma 65
Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma 71
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma 71
Figure 14: Number of Products by Top 10 Routes of Administration, Asthma 76
Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma 77
Figure 16: Number of Products by Top 10 Molecule Types, Asthma 78
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma 79
Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81
Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81
Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 85
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 86
Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91
Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91
Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 92
Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 93
Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis 94
Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis 94
Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 97
Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 98
Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis 102
Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis 102
Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 103
Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 104
|
Respiratory Disorders Treatment Market - By Disease (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Lung Cancer, Respiratory Tract Infection, Allergic Rhinitis, Cystic Fibrosis [CF]), By Drug Class (Bronchodilators, Combination Drugs, Immunotherapy, Corticosteroids, Antibiotics, CFTR, Target Therapy, And Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, And Online Pharmacies), By Route Of Administration (Oral, Nasal, And Injectable), And By Region- Global Industry Perspective, Comprehensive Analysis, And Forecast, 2021 2030
Market Overview Fatpos Global has released a report titled Respiratory Disorders Treatment Market - Analysis of Market Size, Share & Trends for 2014 - 2020 and Forecasts t- 2031. According t- a study by Fatpos Global, is anticipated t- reach U... |
